Histamine H2-receptor antagonist which inhibits gastric acid secretion. Prepn: B. J. Price et al., FR 2384765; eidem, US 4128658 (both 1978 to Allen & Hanburys). HPLC determn in plasma: P. F. Carey, L. E. Martin, J. Liq. Chromatogr. 1979, 1291. HPTLC determn in urine and bioequivalence study: S. A. Shah et al., J. Chromatogr. B 767, 83 (2002). CV determn in pharmaceutical formulations: P. Norouzi et al., J. Pharmacol. Toxicol. Methods 55, 289 (2007). Pharmacological studies: J. Bradshaw et al., Br. J. Pharmacol. 66, 464 (1979); M. J. Daly et al., Gut 21, 408 (1980). Characterization and soly studies of polymorphic forms: M. Mirmehrabi et al., Int. J. Pharm. 282, 73 (2004). Efficacy in treatment of duodenal ulcers: A. Berstad et al., Scand. J. Gastroenterol. 15, 637 (1980); R. P. Walt et al., Gut 22, 49 (1981); of premeal therapy in reduction of heartburn: K. A. Pappa et al., Curr. Ther. Res. 59, 454 (1998). Review of pharmacology and therapeutic use: R. N. Brogden et al., Drugs 24, 267-303 (1982). Comprehensive description: M. Hohnjec et al., Anal. Profiles Drug Subs. 15, 533-561 (1986).
Pharmacology and activity vs Helicobacter sp: R. Stables et al., Aliment. Pharmacol. Ther. 7, 237 (1993).
Antiulcerative.
Antiulcerative; Histamine H2-Receptor Antagonist